As of 2025-12-29, the Intrinsic Value of ABIOMED Inc (ABMD) is 138.49 USD. This Abiomed valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 381.02 USD, the upside of ABIOMED Inc is -63.70%.
The range of the Intrinsic Value is 90.64 - 325.76 USD
Based on its market price of 381.02 USD and our intrinsic valuation, ABIOMED Inc (ABMD) is overvalued by 63.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 90.64 - 325.76 | 138.49 | -63.7% |
| DCF (Growth 10y) | 163.91 - 579.96 | 248.80 | -34.7% |
| DCF (EBITDA 5y) | 102.63 - 171.24 | 131.42 | -65.5% |
| DCF (EBITDA 10y) | 171.72 - 288.69 | 220.30 | -42.2% |
| Fair Value | 147.90 - 147.90 | 147.90 | -61.18% |
| P/E | 143.67 - 360.41 | 239.67 | -37.1% |
| EV/EBITDA | 54.54 - 162.62 | 105.69 | -72.3% |
| EPV | 56.61 - 65.33 | 60.97 | -84.0% |
| DDM - Stable | 58.14 - 176.20 | 117.17 | -69.2% |
| DDM - Multi | 72.64 - 171.38 | 102.07 | -73.2% |
| Market Cap (mil) | 17,180.65 |
| Beta | 1.39 |
| Outstanding shares (mil) | 45.09 |
| Enterprise Value (mil) | 16,998.27 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.06% |
| Cost of Debt | 5.00% |
| WACC | 6.52% |